<code id='966DD4A472'></code><style id='966DD4A472'></style>
    • <acronym id='966DD4A472'></acronym>
      <center id='966DD4A472'><center id='966DD4A472'><tfoot id='966DD4A472'></tfoot></center><abbr id='966DD4A472'><dir id='966DD4A472'><tfoot id='966DD4A472'></tfoot><noframes id='966DD4A472'>

    • <optgroup id='966DD4A472'><strike id='966DD4A472'><sup id='966DD4A472'></sup></strike><code id='966DD4A472'></code></optgroup>
        1. <b id='966DD4A472'><label id='966DD4A472'><select id='966DD4A472'><dt id='966DD4A472'><span id='966DD4A472'></span></dt></select></label></b><u id='966DD4A472'></u>
          <i id='966DD4A472'><strike id='966DD4A472'><tt id='966DD4A472'><pre id='966DD4A472'></pre></tt></strike></i>

          Home / entertainment / knowledge

          knowledge


          knowledge

          author:entertainment    Page View:6

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In